ReviewJournal of cellular and molecular medicine2026
Application of Panax notoginseng Saponins in Skin Wound Repair: Mechanisms and Research Progress.
Review in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Skin wound repair involves four stages: haemostasis, inflammation, proliferation and remodelling. Refractory wounds feature prolonged healing cycles, severe scar hyperplasia and limited clinical therapeutic strategies. Panax notoginseng saponins (PNS), primarily the ginsenosides Rg1 and Rb1 monomers, display high safety and multitarget regulatory properties across the entire wound repair cycle. PNS modulates the inflammatory microenvironment and induces M2-type polarization of macrophages by inhibiting NF-κB, MAPK and other signalling pathways; activates the PI3K/AKT pathway to promote the proliferation and migration of keratinocytes and fibroblasts, and maintains the physiological ratio of collagen type I/III; and upregulates angiogenic factors, including VEGF and bFGF, improving local blood circulation to enhance angiogenesis. Meanwhile, it regulates collagen metabolism, blocks the TGF-β1/Smad2/3 scar-related pathway, and counteracts oxidative stress, thereby accelerating wound healing while inhibiting scar formation. In recent years, PNS has shown promising potential in acute trauma, diabetic foot ulcers, burns and scar repair. PLGA/chitosan nanocarriers, hydrogels, electrospun fibrous membranes and smart responsive delivery systems have effectively addressed limitations of traditional dosage forms, including low bioavailability, poor skin permeability and uneven drug release. Nevertheless, research gaps remains: unclear targets of core monomers r; ambiguous pathway interactions among monomers; and poorly understood crosstalk between signalling pathways; studies on the impacts of extraction processes on pharmacodynamic effects are lacking; and high-level clinical evidence is inadequate. Thus, PNS possesses substantial potential for treating refractory wounds because of its multi-component synergy and full-cycle regulation. Future research should focus on in-depth exploration of molecular mechanisms, standardization of extraction processes, optimization of smart delivery systems and implementation of high-quality clinical studies to promote the translation of active ingredients from traditional Chinese medicine into modern precision therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.